<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>研发客研究院 | wechat-feeds</title><link>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</link><description>独立报告、专业分析、深度解读</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 21 May 2021 13:36:58 +0800</pubDate><image><url>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</url><title>研发客研究院 | wechat-feeds</title><link>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>迪哲医药：用JAK抑制剂挑战外周T细胞淋巴瘤 | SWOT分析</title><link>https://mp.weixin.qq.com/s/yLXqg37DilUyo1qIyTgDcg</link><description></description><content:encoded><![CDATA[迪哲医药：用JAK抑制剂挑战外周T细胞淋巴瘤 | SWOT分析]]></content:encoded><pubDate>Fri, 21 May 2021 11:46:14 +0800</pubDate></item><item><title>The Advantages of Getting BTD for Drugs in China</title><link>https://mp.weixin.qq.com/s/6IhsJ_u0Axm_q0vWWEr_KA</link><description></description><content:encoded><![CDATA[The Advantages of Getting BTD for Drugs in China]]></content:encoded><pubDate>Wed, 19 May 2021 09:54:29 +0800</pubDate></item><item><title>China Regulations Tracker: Mar 2021</title><link>https://mp.weixin.qq.com/s/nADbxjcWnc2JeJfbsD-_aw</link><description></description><content:encoded><![CDATA[China Regulations Tracker: Mar 2021]]></content:encoded><pubDate>Mon, 17 May 2021 09:14:22 +0800</pubDate></item><item><title>China Market Approval Tracker: Mar 2021</title><link>https://mp.weixin.qq.com/s/fc5Oljis4nX6NAqBCPtuIg</link><description></description><content:encoded><![CDATA[China Market Approval Tracker: Mar 2021]]></content:encoded><pubDate>Thu, 13 May 2021 15:26:33 +0800</pubDate></item><item><title>Theseus：预测肿瘤突变，开发广谱TKI抑制剂 | 前沿</title><link>https://mp.weixin.qq.com/s/tdR4o5QIX7otiDkZUpMruQ</link><description></description><content:encoded><![CDATA[Theseus：预测肿瘤突变，开发广谱TKI抑制剂 | 前沿]]></content:encoded><pubDate>Thu, 06 May 2021 17:12:27 +0800</pubDate></item><item><title>腾盛博药：专注传染性公共卫生疾病｜SWOT分析</title><link>https://mp.weixin.qq.com/s/Vv7sCGxSK3h1cDDsqVTzTA</link><description></description><content:encoded><![CDATA[腾盛博药：专注传染性公共卫生疾病｜SWOT分析]]></content:encoded><pubDate>Fri, 30 Apr 2021 09:03:33 +0800</pubDate></item><item><title>昭衍新药：核心业务占绝对比重，着力拓展海外市场｜SWOT分析</title><link>https://mp.weixin.qq.com/s/_KScordfuM6brEtjkSFddw</link><description></description><content:encoded><![CDATA[昭衍新药：核心业务占绝对比重，着力拓展海外市场｜SWOT分析]]></content:encoded><pubDate>Fri, 23 Apr 2021 11:53:32 +0800</pubDate></item><item><title>China Regulations Tracker: Feb 2021</title><link>https://mp.weixin.qq.com/s/y8Ef0MCbAhMEHVvCoSdh_A</link><description></description><content:encoded><![CDATA[China Regulations Tracker: Feb 2021]]></content:encoded><pubDate>Thu, 15 Apr 2021 16:38:30 +0800</pubDate></item><item><title>China Biotech Fundraising Tracker: Feb 2021</title><link>https://mp.weixin.qq.com/s/DOL57XfwDwuYmH43jFnKZQ</link><description></description><content:encoded><![CDATA[China Biotech Fundraising Tracker: Feb 2021]]></content:encoded><pubDate>Sun, 11 Apr 2021 19:54:27 +0800</pubDate></item><item><title>凯因科技：差异化营销策略能否化解产品困局？ | SWOT分析</title><link>https://mp.weixin.qq.com/s/teEFahEAcXTFMM5mz_rffg</link><description></description><content:encoded><![CDATA[凯因科技：差异化营销策略能否化解产品困局？ | SWOT分析]]></content:encoded><pubDate>Fri, 09 Apr 2021 00:30:36 +0800</pubDate></item></channel></rss>